Mesoblast (ASX:MSB) share price rebounds 15%, what's been happening?

Shares in this biotech are bouncing back today…

| More on:
Three scientists wearing white coats and blue gloves dance together in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mesoblast share price is up 16.5% to $1.20 on Wednesday 
  • Despite the jump, there are no announcements from the company 
  • Last week Mesoblast was one of the most shorted shares on the ASX 

The Mesoblast Limited (ASX: MSB) share price has been regaining some of its recent losses today.

In afternoon trade, shares in the regenerative medicines company are fetching $1.20, up 16.5%. Despite the gain, shareholders are still a distant 52% below Mesoblast's 52-week high of $2.52.

Could the shorts be covering?

While the market is throwing support behind the Mesoblast share price today, the shifting sentiment is not a result of a positive announcement.

In fact, the ASX-listed drug developer hasn't released any news since 25 February. Aside from that release, the only other news to arise is the company's removal from the S&P/ASX 200 Index (ASX: XJO) — which was revealed on Friday.

However, thanks to my Foolish colleague, James, we know that Mesoblast made the top 10 most shorted ASX shares last week. From the ASIC data, the recent weakness in the Mesoblast share price coincided with a 9.8% short interest last week.

This might suggest shorters might be taking some of their profits off the table today after a prolonged downward run in Mesoblast shares.

Between 11 December 2020 and today, the unprofitable biotech has suffered a 74% fall in its share price. Given this, the far majority of short-sellers were likely in profit leading up to today.

How does the Mesoblast share price compare to its peers?

Looking at the company on a year-to-date (YTD) basis, the performance of the Mesoblast share price is roughly in line, if not better in some cases, than its ASX-listed pharmaceutical peers.

Since the year kicked off, Mesoblast shares have fallen 15.2%. For comparison, let's look at the performance of other similar companies.

  • CSL Limited (ASX: CSL) down 13% YTD
  • Telix Pharmaceuticals Ltd (ASX: TLX) down 40.8% YTD
  • Mayne Pharma Group Ltd (ASX: MYX) down 32.3% YTD

Finally, based on the current Mesoblast share price, the company holds a market capitalisation of $772 million.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous, but positive, Tuesday for ASX investors.

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Share Gainers

Why Bapcor, Ramelius, Sandfire, and WIA Gold shares are rising today

These shares are having a better day than most on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors started the week off in a good mood today.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Bellevue Gold, Bubs, Clarity Pharmaceuticals, and Regal Partners shares are rising today

These shares are starting the week on a positive note.

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Travel Shares

Guess which ASX All Ords travel stock just rocketed 17% on an earnings upgrade

Investors are piling into the ASX All Ords travel stock today. Here's what's happening.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »